Shanghai, January 21, 2022: WuXi STA, a subsidiary of WuXi AppTec, today announced its first parenteral formulation manufacturing line at the Wuxi…
Shanghai, December 03, 2021: WuXi STA – a subsidiary of WuXi AppTec– and Coherent Biopharma, announced the signing of a strategic…
Shanghai, July 23, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit…
Shanghai, May 22, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical,…
Shanghai, November 15, 2018: WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of Fruquintinib capsules (Elunate®) for metastatic…
Shanghai, July 29, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API)…
Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…
WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® Shanghai, June 15, 2018: STA Pharmaceutical Co., Ltd. (WuXi…
The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval Shanghai, May 11,…
MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC) Vancover, April 19, 2018: Phoenix…